Royalty Pharma (RPRX) Capital Expenditures (2019 - 2026)
Royalty Pharma (RPRX) posted Capital Expenditures of $452.4 million for Q1 2026, down 38.34% sequentially from $733.7 million in Q4 2025, and up 42697.16% YoY from N/an in Q1 2025.
Royalty Pharma (RPRX) Capital Expenditures (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Capital Expenditures for 8 years, with the latest figure at $452.4 million in Q1 2026.
- Quarterly Capital Expenditures rose 42697.16% year-over-year to $452.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 11.22% YoY) and the FY2025 annual result came in at $1.7 billion, down 32.25% from the prior year.
- Capital Expenditures eased to $452.4 million in Q1 2026 per RPRX's latest filing, from $733.7 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.3 billion in Q3 2022 and troughed at $85000.0 in Q1 2022.
- A 5-year average of $500.8 million and a median of $452.4 million in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 99.98% in 2022, then jumped 707788.24% in 2023.
- Over 5 years, Capital Expenditures stood at $250.2 million in 2022, then soared by 300.51% to $1.0 billion in 2023, then slumped by 50.47% to $496.4 million in 2024, then soared by 47.8% to $733.7 million in 2025, then sank by 38.34% to $452.4 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $452.4 million, $733.7 million, and $961.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 251.02 Mn |
| Jun 30, 2026 | 251.02 Mn |
| Mar 31, 2026 | 452.37 Mn |
| Mar 31, 2026 | 452.37 Mn |
| Dec 31, 2025 | 733.69 Mn |
| Dec 31, 2025 | 733.69 Mn |
| Sep 30, 2025 | 961.87 Mn |
| Sep 30, 2025 | 961.87 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 496.42 Mn |
| Dec 31, 2024 | 496.42 Mn |
| Sep 30, 2024 | 1.19 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 728.63 Mn |
| Jun 30, 2024 | 728.63 Mn |
| Mar 31, 2024 | 86.08 Mn |
| Mar 31, 2024 | 86.08 Mn |